Accurate enumeration of
circulating tumor cells (CTCs) in
cancer patient's blood functions as a form of "liquid biopsy", which is pivotal for
cancer screening, prognosis, and diagnosis. Herein, we demonstrate a novel antibody functionalized microfluidic (AFM) chip that rapidly and accurately qualifies CTCs from
breast cancer patient's whole blood. The AFM chip consists of three buffering zones, and four main capturing zones filled with equilateral triangular pillars and periodically distributed obstacles. We validate the AFM chip with three
Epithelial cell adhesion molecule (
EpCAM) positive
cancer cell lines, including breast (MCF-7), prostate (PC3), and
lung cancer cell lines (A549), achieving capture efficiencies of 99.5%, 98.5%, and 96.72%, respectively, at a flow rate of 0.6 mL/hour. We further confirm the efficacy of the AFM chip with five advanced
breast cancer patients' whole blood to capture
EpCAM+/CK19+/CD45-/DAPI + CTCs. Interestingly, high number of CTCs were identified from each patient's 1 mL whole blood (595-2270), The AFM chip is highly efficient at rapidly capturing CTCs from
cancer patients' whole blood without requiring extra equipment, which is critically beneficial for clinical application.